Alnylam Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ALNYLAM PHARMS INC, and when can generic versions of ALNYLAM PHARMS INC drugs launch?
ALNYLAM PHARMS INC has four approved drugs.
There are forty-four US patents protecting ALNYLAM PHARMS INC drugs.
There are seven hundred and seventy-two patent family members on ALNYLAM PHARMS INC drugs in fifty-four countries and seventy-five supplementary protection certificates in seventeen countries.
Summary for Alnylam Pharms Inc
International Patents: | 772 |
US Patents: | 44 |
Tradenames: | 4 |
Ingredients: | 4 |
NDAs: | 4 |
Drugs and US Patents for Alnylam Pharms Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | 10,435,692 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | RX | Yes | Yes | 8,158,601 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | 10,131,907 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | RX | Yes | Yes | 8,168,775 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Alnylam Pharms Inc | AMVUTTRA | vutrisiran sodium | SOLUTION;SUBCUTANEOUS | 215515-001 | Jun 13, 2022 | RX | Yes | Yes | 11,286,486 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Alnylam Pharms Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | 9,193,753 | ⤷ Try a Trial |
Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | 8,552,171 | ⤷ Try a Trial |
Alnylam Pharms Inc | GIVLAARI | givosiran sodium | SOLUTION;SUBCUTANEOUS | 212194-001 | Nov 20, 2019 | 8,546,143 | ⤷ Try a Trial |
Alnylam Pharms Inc | GIVLAARI | givosiran sodium | SOLUTION;SUBCUTANEOUS | 212194-001 | Nov 20, 2019 | 9,708,615 | ⤷ Try a Trial |
Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | 8,362,231 | ⤷ Try a Trial |
Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | 9,943,539 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Alnylam Pharms Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | 2021167313 | ⤷ Try a Trial |
Israel | 257166 | ⤷ Try a Trial |
Japan | 2006522158 | ⤷ Try a Trial |
New Zealand | 730296 | ⤷ Try a Trial |
Japan | 2022160408 | ⤷ Try a Trial |
European Patent Office | 3450559 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Alnylam Pharms Inc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3204015 | C20220010 00364 | Estonia | ⤷ Try a Trial | PRODUCT NAME: LUMASIRAAN;REG NO/DATE: EU/1/20/1496 23.11.2020 |
2937418 | PA2019501 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: PATISIRANAS; REGISTRATION NO/DATE: EU/1/18/1320 20180827 |
3204015 | LUC00252 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: LUMASIRAN SOUS TOUTES SES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/20/1496 20201123 |
2937418 | 2019C/501 | Belgium | ⤷ Try a Trial | PRODUCT NAME: PATISIRAN; AUTHORISATION NUMBER AND DATE: EU/1/18/1320 20180829 |
3052628 | LUC00175 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: GIVOSIRAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/20/1428 20200304 |
3329002 | 301216 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: VUTRISIRAN; REGISTRATION NO/DATE: EU/1/22/1681 20220916 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.